Literature DB >> 15262667

A three-part intervention to change the use of hormone replacement therapy in response to new evidence.

Christianne L Roumie1, Eric L Grogan, William Falbe, Joseph Awad, Theodore Speroff, Robert S Dittus, Tom A Elasy.   

Abstract

BACKGROUND: Slow adaptation of new information by providers may result in suboptimal care.
OBJECTIVE: To evaluate changes in prescriptions for combination hormone replacement therapy (HRT) after a multicomponent intervention to deliver new information to patients and providers.
DESIGN: Quasi-experimental study with multiple baselines.
SETTING: Veterans Affairs Tennessee Valley Healthcare System (VA-TVHS). PATIENTS: Female veterans age 50 to 79 years who had a prescription filled at the VA-TVHS for combination HRT between 1 January 2002 and 1 July 2002. MEASUREMENTS: Discontinuation of HRT. INTERVENTION: A 3-part intervention consisted of 1) notifying patients who were using combination HRT of the results of the Women's Health Initiative study (patient education component), 2) sending all providers an e-mail with the Women's Health Initiative study results (provider education component), and 3) placing an electronic alert in each eligible patient's chart (provider care component). The alert asked providers to reevaluate the need for combination HRT. The intervention was implemented at different VA-TVHS sites in a stepwise fashion to differentiate intervention effect from media effect. Study follow-up continued through 31 December 2002.
RESULTS: The total rate of discontinuation of combination HRT was 70.3% in 2002. The proportion of discontinuation from time of media release until intervention was 23.3%. After initiation of the intervention, an additional 43% of the original cohort discontinued use of HRT; this percentage represents a 59% relative decrease in HRT use among patients. After adjustment for time, the discontinuation rate per day was 4.9 times higher after the multifacted intervention than after the media release (95% CI, 1.8 to 13.1). LIMITATIONS: A true control group is lacking.
CONCLUSION: A multifaceted approach in an integrated health care system with standardized methods of communication is an effective way to implement patient-centered, effective, and timely care with changing medical knowledge.

Entities:  

Mesh:

Year:  2004        PMID: 15262667     DOI: 10.7326/0003-4819-141-2-200407200-00010

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  5 in total

Review 1.  The state of women veterans' health research. Results of a systematic literature review.

Authors:  Caroline L Goldzweig; Talene M Balekian; Cony Rolón; Elizabeth M Yano; Paul G Shekelle
Journal:  J Gen Intern Med       Date:  2006-03       Impact factor: 5.128

2.  The impact of clinical trials on the use of hormone replacement therapy. A population-based study.

Authors:  Nancy Kim; Cary Gross; Jeptha Curtis; Glen Stettin; Stephen Wogen; Nami Choe; Harlan M Krumholz
Journal:  J Gen Intern Med       Date:  2005-11       Impact factor: 5.128

3.  Treatment decisions for complex patients: differences between primary care physicians and midlevel providers.

Authors:  Usha Subramanian; Eve A Kerr; Mandi L Klamerus; Brian J Zikmund-Fisher; Robert G Holleman; Timothy P Hofer
Journal:  Am J Manag Care       Date:  2009-06       Impact factor: 2.229

4.  Rationale, design, and implementation protocol of the Dutch clinical practice guideline pain in patients with cancer: a cluster randomised controlled trial with Short Message Service (SMS) and Interactive Voice Response (IVR).

Authors:  Nienke te Boveldt; Yvonne Engels; Kees Besse; Kris Vissers; Myrra Vernooij-Dassen
Journal:  Implement Sci       Date:  2011-12-06       Impact factor: 7.327

Review 5.  Towards understanding the de-adoption of low-value clinical practices: a scoping review.

Authors:  Daniel J Niven; Kelly J Mrklas; Jessalyn K Holodinsky; Sharon E Straus; Brenda R Hemmelgarn; Lianne P Jeffs; Henry Thomas Stelfox
Journal:  BMC Med       Date:  2015-10-06       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.